In the BioHarmony Drug Report Database

"Preview" Icon

Dantrolene

Dantrium, Ryanodex (dantrolene) is a small molecule pharmaceutical. Dantrolene was first approved as Dantrium on 1982-01-01. It is used to treat cerebral infarction, cerebral palsy, malignant hyperthermia, multiple sclerosis, and muscle spasticity amongst others in the USA. The pharmaceutical is active against ryanodine receptor 1. In addition, it is known to target ryanodine receptor 3. Dantrolene sodium’s patents are valid until 2025-07-01 (FDA).

 

Trade Name

 

Dantrium, Ryanodex
 

Common Name

 

dantrolene
 

ChEMBL ID

 

CHEMBL1201288
 

Indication

 

cerebral infarction, cerebral palsy, malignant hyperthermia, multiple sclerosis, muscle spasticity, neuroleptic malignant syndrome, spinal cord injuries
 

Drug Class

 

Image (chem structure or protein)

Dantrolene structure rendering